Veterinary medicine market seen reaching $95.63 billion by 2035

Market Research Future projects the global veterinary medicine market will grow from $49.96 billion in 2026 to $95.63 billion by 2035, driven by pet ownership, antibiotic stewardship rules and a shift toward biologics. The forecast points to stronger demand in companion animal care, vaccines and diagnostic-linked treatments across major regions. Why it matters: - The forecast signals sustained demand in animal health, not just a cyclical spending bump. - Faster growth in vaccines, biologics and diagnostics could reshape how veterinarians treat both companion animals and livestock. - The projected expansion matters for drug makers, clinics, livestock producers and pet owners facing higher expectations for preventive care. What happened: - Market Research Future projected the global veterinary medicine market will rise from $49.96 billion in 2026 to $95.63 billion by 2035. - The forecast implies a 7.48% compound annual growth rate during 2026-2035. - The market was estimated at $46.48 billion in 2025. - The company published the outlook on June 18, 2026. - The report links growth to pet humanization, antibiotic stewardship rules and biologics expansion. - A free sample is available here . The details: - Rising pet ownership is expanding the addressable market for companion animal pharmaceuticals. - The American Pet Products Association reported that 67% of U.S. households, or about 87 million homes, owned a pet in 2024. - That compares with 56% a decade earlier. - Average annual pharmaceutical spending per pet now exceeds $400 in the United States. - China’s urban pet population exceeded 120 million in 2024, creating a companion animal pharmaceuticals pool valued at more than $5.2 billion. - India and South Korea are also seeing higher adoption tied to urbanization. - Longer companion animal lifespans are increasing demand for chronic-disease medications. - AI-assisted diagnostics are being used to detect subclinical disease earlier and shift care toward preventive treatment. - The report says machine-learning tools trained on more than 2 million veterinary imaging datasets can detect metabolic and neoplastic conditions 12-18 months earlier than conventional screening. - Antibiotic stewardship rules are pushing livestock care away from growth-promoting antibiotics and toward vaccines and probiotics. - The EU’s Regulation 2019/6 and the FDA’s five-year antimicrobial resistance action plan have removed more than 70 previously approved antibiotic feed-grade indications since 2022. - The EU’s Farm to Fork strategy targets a 50% reduction in antimicrobial sales for food-producing animals by 2030. - Biologics are gaining share from small-molecule generics. - The report highlights stronger demand for recombinant vaccines, monoclonal antibodies and gene-edited vaccines. - Pet owners are showing willingness to pay for higher-priced biologic medicines, citing products such as Librela for dogs and Solensia for cats. - The U.S. Department of Agriculture has committed to streamlined approval pathways for novel veterinary biologics. - By product type, drugs held about 52.5% of revenue in 2025. - Parasiticides generated more than $8 billion globally in 2025. - Vaccines are the fastest-growing product segment, with a projected 9.70% CAGR from 2026 to 2035. - Medicated feed additives reached $7.88 billion in 2025. - By animal type, companion animals held about 51.5% of revenue in 2025. - Livestock animals are the fastest-growing animal segment, with a projected 11.24% CAGR from 2026 to 2035. - By route of administration, parenteral products held about 44.0% of revenue in 2025. - Oral products reached $14.20 billion in 2025. - By end user, veterinary hospitals held about 53.5% of the market in 2025. - Veterinary clinics are the fastest-growing end-user segment, with a projected 11.65% CAGR from 2026 to 2035. - North America held about 38.1% of the market in 2025. - The United States generated about 82.4% of North American revenue. - Europe held about 27.0% of the market in 2025. - Asia-Pacific is projected to grow at 10.80% CAGR from 2026 to 2035. - The Middle East and Africa market reached $2.60 billion in 2025. - South America reached $3.16 billion in 2025. - The top four companies hold an estimated 55% to 60% of global revenue. - Merck Animal Health held about 9% to 12% of global revenue and acquired Elitechvet diagnostic assets in June 2023. - Elanco Animal Health held about 7% to 10% of global revenue, launched Credelio Quattro in March 2024 and received FDA approval for the cat version in December 2025. - IDEXX Laboratories held about 4% to 6% of global revenue and launched the Procyte One hematology analyzer in September 2023. Between the lines: - The market is shifting from low-margin generics toward higher-value biologics and diagnostic-linked treatment models. - That shift can improve pricing power for manufacturers, but it may also raise costs for pet owners and livestock operators before biosimilars and competition bring prices down. - The report also suggests the next growth phase will depend on how quickly AI-enabled diagnostics and preventive protocols move from early adoption to routine use. - Venture capital interest underscores that investors expect animal health to look more like a specialized recurring-care market than a simple medicines category. What’s next: - The report expects precision biologics and integrated diagnostic-therapeutic platforms to become a central operating model by 2030. - It projects about 40% of newly diagnosed chronic conditions in companion animals will receive diagnostic screening followed by matched biologic therapy by 2030. - Patent expirations expected in 2025-2027 could open the door for biosimilars and lower pet health medication costs by 20% to 30%. - AI-integrated clinical decision support is expected to guide vaccination and treatment sequencing by 2028-2030. - Start-ups have raised more than $800 million in veterinary decision-support funding since 2023. - More information is available in the full report . The bottom line: - Veterinary medicine is moving toward a larger, more preventive and more technology-driven market, with vaccines, biologics and diagnostics set to drive much of the growth through 2035.